ArticleEJHaem2020

RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation.

Baptiste Le Calvez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.